CD155 and CD112 as possible therapeutic targets of FLT3 inhibitors for acute myeloid leukemia

Kaito, Y; Hirano, M; Futami, M; Nojima, M; Tamura, H; Tojo, A; Imai, Y

Imai, Y (通讯作者),Univ Tokyo, Res Hosp, Inst Med Sci, Dept Hematol Oncol,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.

ONCOLOGY LETTERS, 2022; 23 (2):

Abstract

Acute myeloid leukemia (AML) relapse is considered to be related to escape from antitumor immunity. Changes in the expression of immune checkpoints, i......

Full Text Link